United States

Bend Research launches biotherapeutics development initiative

Monday, March 26, 2012 10:52 AM

Bend Research, an independent drug-formulation development and manufacturing company based in Bend, Ore., has launched an initiative to expand its scientific and engineering expertise into biotherapeutics.

More... »

ACRO launches educational YouTube channel

Thursday, March 22, 2012 02:49 PM

In an effort to educate the public, media and policymakers about clinical trials and the growing role of CROs in the drug development process, the Association of Clinical Research Organizations (ACRO) has launched a YouTube channel @ACROHealthChannel.

More... »

Repligen enrolls first patient in phase I trial of Friedreich’s Ataxia

Monday, March 19, 2012 03:20 PM

Waltham, Mass.-based Repligen has enrolled the first patient in a phase I clinical trial of RG2833 in adult patients with Friedreich’s Ataxia (FA)—a debilitating, life-shortening, degenerative neuro-muscular disorder that currently has no treatment.

More... »

inVentiv to acquire Kforce

Monday, March 19, 2012 12:39 PM

Burlington, Mass.-based inVentiv Health, which offers clinical, commercial and consulting services to the healthcare industry, has signed a definitive agreement to acquire Kforce Clinical Research (KCR), a provider of functional outsourcing solutions to pharmaceutical, biotech and medical device companies, from Kforce Inc. for $50 million in cash.

More... »

ImmusanT names Patrick Griffin as chief medical officer, senior VP

Monday, March 19, 2012 12:37 PM

ImmusanT, a privately-held biotech based in Cambridge, Mass., has named Patrick H. Griffin, MD, as chief medical officer and senior vice president of development.

More... »

diaDexus highlights findings of two PLAC Lp-PLA(2) activity studies

Monday, March 19, 2012 11:49 AM

San Francisco–based diaDexus, a company focused on proprietary cardiovascular diagnostic products, reported highlights from two recent studies evaluating the clinical utility of its PLACR Test for Lp-PLA(2) activity.

More... »

NIH awards Avaxia Biologics $1.5 million for bowel disease

Monday, March 19, 2012 10:57 AM

Avaxia Biologics, a privately-held biotech company based in Lexington, Mass., has received a second round of funding from the National Institutes of Health (NIH) to develop orally-active antibody therapeutics for the treatment of inflammatory bowel disease (IBD).

More... »

Provectus reports top-line data in phase II psoriasis study

Monday, March 19, 2012 10:39 AM

Provectus Pharmaceuticals, a development-stage oncology and dermatology biopharmaceutical company, reported top-line data for the company's randomized controlled trial of PH-10, a topical aqueous hydrogel, for mild-to-moderate plaque psoriasis.

More... »

Columbia, Weill Cornell join national effort to spur clinical trials in neurosciences

Friday, March 16, 2012 11:49 AM

The National Institute for Neurological Disorders and Stroke (NINDS) has selected Columbia University College of Physicians and Surgeons and Weill Cornell Medical College to participate in a new national effort to accelerate the development of therapies for people with neurological diseases.

More... »

Gintuit receives FDA approval for gum tissue regeneration

Thursday, March 15, 2012 06:00 AM

The FDA has approved Gintuit, a cell-based topical product that has been shown to predictably generate new and aesthetically appealing oral soft tissue, according to Organogenesis.

More... »